Search

Immunotherapy / Systemic Therapy

P412

THE EFFECTS OF CISPLATIN ON GASTROSTOMY SITE HEALING

Immunotherapy / Systemic Therapy

J Renee Booth, MD1; Hesamoldin Khodadadi2; E Jim Kruse, DO1; A Kumar Guddati, MD1; Babak Baban, PhD2; J Kenneth Byrd, MD1

1School of Medicine at Augusta University; 2Dental College of Georgia


P411

SAFETY AND EFFICACY OF ANTI-PD-1 TREATMENT IN CHALLENGING POPULATIONS WITH SQUAMOUS CELL CARCINOMA

Immunotherapy / Systemic Therapy

Olivia A Do; Sebastian M Jara, MD; Cristina P Rodriguez, MD; Jeffery J Houlton, MD; Brittany R Barber, MD

University of Washington


P410

ONCOLOGIC OUTCOMES OF SALVAGE SURGERY AND IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY IN RECURRENT HNSCC: A SINGLE INSTITUTION RETROSPECTIVE STUDY

Immunotherapy / Systemic Therapy

Neeraja Konuthula, MD; Olivia Do; Ted Gobillot; Cristina Rodriguez; Neal Futran; Jeffrey Houlton; Brittany Barber

University of Washington


P409

RELATIONSHIP BETWEEN THE IMMUNE MICROENVIRONMENT AND DISEASE RECURRENCE IN HEAD AND NECK SQUAMOUS CELL CARCINOMA.

Immunotherapy / Systemic Therapy

Colleen G Hochfelder, MD, MS1; Fengshen Kuo, PhD2; Nicolas F Schlecht, PhD3; Thomas J Belbin, PhD3; Geoffrey Childs, PhD3; Michael B Prystowsky, MD, PhD3; Richard V Smith4; Vikas Mehta, MD, MPH4; Bradley A Schiff, MD4; Luc GT Morris, MD, MSc2; Thomas J Ow, MD, MS4

1University of Michigan; 2Memorial Sloan Kettering Cancer Center; 3Albert Einstein College of Medicine; 4Montefiore Medical Center / Albert Einstein College of Medicine


P408

SERUM PD-L1 AS A POTENTIAL PROGNOSTIC MARKER IN PAPILLARY THYROID CARCINOMA

Immunotherapy / Systemic Therapy

Janmaris Marin Fermin, MD1; Lindsay Boven, MD1; Abhijit Gundale, MD1; Md Maksudul Alam, PhD1; Tara Moore-Medlin, BS1; Jose M Flores, MD, PhD, MPH2; Stephanie Terhoeve, BS3; Xin Gu, MD4; Brent Chang, MD1; Cherie-Ann O Nathan, MD, FACS1

1Department of Otolaryngology-Head and Neck Surgery, LSU-Health Sciences Center, Shreveport, LA, USA.; 2Yale Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.; 3School of Medicine, LSU-Health Science Center, Shreveport, LA, USA; 4Department of Pathology, LSU-Health Sciences Center, Shreveport, LA, USA


P407

LIBRETTO-531: A PHASE III STUDY OF SELPERCATINIB VS INVESTIGATOR CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH MULTIKINASE INHIBITOR-NAÏVE ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC)

Immunotherapy / Systemic Therapy

Marcia S Brose, MD, PhD1; Jaume Capdevila2; Rossella Elisei3; Lori J Wirth4; Sophie Leboulleux5; Andreas Sashegyi6; Victoria Soldatenkova6; Boris K Lin6; Jennifer Wright6; Bruce Robinson7; Makoto Tahara8; Ana O Hoff9; Mimi Hu10; Eric J Sherman11

1University of Pennsylvania; 2Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron University Hospital; 3University of Pisa; 4Massachusetts General Hospital; 5Gustave Roussy; 6Eli Lilly and Company; 7Royal North Shore Hospital; 8National Cancer Center Hospital East; 9Instituto de Cancer do Estado de Sao Paulo; 10The University of Texas MD Anderson Cancer Center; 11Memorial Sloan Kettering Cancer Center


P406

DETERMINING THE ROLE OF CENTRAL MEMORY T CELLS IN RESPONSE TO ANTI-PD1 THERAPY

Immunotherapy / Systemic Therapy

Michael R Bobian, MD1; Hannah Knochelmann, BS1; Connor Dwyer, PhD1; Chrystal Paulos, PhD2; David Neskey, MD1

1Medical University of South Carolina; 2Emory University Schlool of Medicine


P405

ELEVATION OF T-CELL-DERIVED CYTOKINES COULD PREDISPOSE PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS TO DEVELOPING IMMUNE-RELATED ADVERSE EVENTS

Immunotherapy / Systemic Therapy

Angela Alnemri, BS1; S Hamad Sagheer, BS, BA1; Kevin Xiao, BS2; Yamil Selman, MD1; Madalina Tuluc, MD3; Tingting Zhan, PhD4; David Cognetti, MD1; Joseph M Curry, MD1; Jennifer M Johnson, MD, PhD5; Athanassios Argiris, MD, PhD5; Larry Harshyne, PhD5; Adam Luginbuhl, MD1

1Department of Otolaryngology, Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A.; 2Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A.


P404

IMMUNE CHECKPOINT INHIBITORS AND THEIR POTENTIAL ROLE IN THE MANAGEMENT OF ORAL PRECANCEROUS LESIONS.

Immunotherapy / Systemic Therapy

Nikhil Mistry1; Alessandro Villa, DDS, PhD, MPH2; Glenn Hanna, MD3

1Harvard School of Dental Medicine; 2University of California, San Francisco Health; 3Dana Farber


P403

VALIDATION OF A MULTIPLEX IMMUNOFLUORESCENCE TECHNIQUE FOR SPATIAL CHARACTERIZATION OF IMMUNE CELL POPULATIONS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

Immunotherapy / Systemic Therapy

Christie McGee, MD1; Serena Zilio, PhD2; Francisco J Civantos, MD1; Zoukaa Sargi, MD1; Elizabeth J Franzmann, MD1; Elizabeth Nicolli, MD1; Giovana Thomas, MD1; Jason Leibowitz, MD1; David Arnold, MD1; Donald T Weed, MD1; Paolo Serafini, PhD2

1Department of Otolaryngology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine; 2Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine